title: Landiolol hydrochloride for early postoperative tachycardia after transthoracic esophagectomy.
abstract: OBJECTIVE
  To validate the safety and efficacy of landiolol, a beta1-selective blocker, as a primary care option for postoperative tachycardia after transthoracic esophagectomy.
  
  
  METHODS
  The subjects were 74 consecutive patients who underwent esophagectomy between May 2008 and December 2009. Patients who developed tachycardia with a heart rate >120 bpm for >5 min were defined as candidates for the use of landiolol. The rate of successful heart control without adverse effects was the primary endpoint. The reduction of the rate pressure product (RPP) and heart rate were used as secondary endpoints.
  
  
  RESULTS
  Thirteen patients (18 %) were treated with landiolol for postoperative tachycardia. No adverse effects were observed. Successful management using landiolol alone was achieved in 10 of the 13 patients (77 %). Of the three patients for whom landiolol treatment was unsuccessful, two were also not successfully managed promptly by other treatments. The heart rate and RPP were reduced by landiolol, with median changes of 38 and 44 %, respectively, without significant negative inotropic effects.
  
  
  CONCLUSIONS
  Although our sample size was small, an improved cardiac performance and no severe negative inotropic effects were observed with the use of landiolol. Landiolol could therefore be an efficient and safe choice for the management of postoperative tachycardia after esophagectomy.
authors.affiliation: Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo Hospital, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan, morikaz158@gmail.com.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Mori
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yamada
authors.forename: Takashi
authors.initials: T
authors.lastname: Fukuda
authors.forename: Takashi
authors.initials: T
authors.lastname: Mitsui
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kitamura
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yamaguchi
authors.forename: Jiro
authors.initials: J
authors.lastname: Ando
authors.forename: Ikuo
authors.initials: I
authors.lastname: Wada
authors.forename: Sachiyo
authors.initials: S
authors.lastname: Nomura
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Shimizu
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Seto
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004938:Esophageal Neoplasms / Q000601:surgery*; D016629:Esophagectomy / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy*; D013610:Tachycardia / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D014508:Urea / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D009025:Morpholines; C077049:landiolol; D014508:Urea